TScan Therapeutics’ (TCRX) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note released on Wednesday, RTT News reports. They currently have a $10.00 price target on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.28) EPS and Q4 2025 earnings at ($0.27) EPS.

Separately, HC Wainwright restated a buy rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Thursday, March 7th.

TScan Therapeutics Price Performance

Shares of TCRX opened at $6.75 on Wednesday. The stock has a fifty day moving average of $7.02 and a two-hundred day moving average of $5.63. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.18. TScan Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $9.00.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The business had revenue of $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. Equities research analysts forecast that TScan Therapeutics will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in TScan Therapeutics during the 2nd quarter worth $32,000. Renaissance Technologies LLC purchased a new stake in TScan Therapeutics during the 1st quarter worth $37,000. LPL Financial LLC purchased a new stake in TScan Therapeutics during the 2nd quarter worth $50,000. Pale Fire Capital SE purchased a new stake in TScan Therapeutics during the 3rd quarter worth $42,000. Finally, Cannon Global Investment Management LLC purchased a new stake in TScan Therapeutics during the 1st quarter worth $139,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.